Human brain fluoxetine concentrations

Back to table of contents Previous article Next article No AccessHuman brain fluoxetine concentrationsPublished Online:1 Apr 2006https://doi.org/10.1176/jnp.5.3.322AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractData on 22 subjects treated with fluoxetine suggest that magnetic resonance spectroscopy (MRS) of fluorine-19 can measure brain concentrations of fluoxetine/norfluoxetine in vivo. Fluoxetine accumulates in the human brain relative to plasma, with brain concentrations of fluoxetine/norfluoxetine ranging up to 10.7 micrograms/ml. Brain concentrations may reach a plateau between 6 and 8 months of treatment. The apparent concentration in brain relative to plasma is 20:1, roughly parallel to brain antidepressant concentration ratios in animal studies. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences $35.00 Add to cart PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byKetamine and its metabolite 2 R ,6 R ‐hydroxynorketamine promote ocular dominance plasticity and release tropomyosin‐related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons13 February 2023 | European Journal of Neuroscience, Vol. 57, No. 6The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre‐insertion and post‐insertion methods for brain delivery in normal mice3 January 2023 | IET Nanobiotechnology, Vol. 46BDNF receptor TrkB as the mediator of the antidepressant drug action2 November 2022 | Frontiers in Molecular Neuroscience, Vol. 15Participation of the Serotonergic System and Brain-Derived Neurotrophic Factor in the Antidepressant-like Effect of Flavonoids17 September 2022 | International Journal of Molecular Sciences, Vol. 23, No. 18Paroxetine Increases δ Opioid Responsiveness in Sensory Neurons26 July 2022 | eneuro, Vol. 9, No. 4Fluoksetinin sıçan torasik aort düz kasındaki vazoaktif etkileri30 June 2022 | Cukurova Medical Journal, Vol. 47, No. 2Improved Serotonin Measurement with Fast-Scan Cyclic Voltammetry: Mitigating Fouling by SSRIs11 April 2022 | Journal of The Electrochemical Society, Vol. 169, No. 4Fluoxetine acts concomitantly on dorsal and ventral hippocampus to Trk-dependently modulate the extinction of fear memoryProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drugCell Reports, Vol. 37, No. 519F Magnetic Resonance Imaging and Spectroscopy in NeuroscienceNeuroscience, Vol. 474Effects of the Selective Serotonin Reuptake Inhibitor Fluoxetine on Developing Neural Circuits in a Model of the Human Fetal Cortex28 September 2021 | International Journal of Molecular Sciences, Vol. 22, No. 19Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant ActionBiological Psychiatry, Vol. 90, No. 2Impact of Wnt/β‐catenin signaling on ethanol‐induced changes in brain endothelial cell permeability29 October 2020 | Journal of Neurochemistry, Vol. 157, No. 4Is the Antidepressant Activity of Selective Serotonin Reuptake Inhibitors Mediated by Nicotinic Acetylcholine Receptors?8 April 2021 | Molecules, Vol. 26, No. 8Antidepressant drugs act by directly binding to TRKB neurotrophin receptorsCell, Vol. 184, No. 5Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day13 October 2022 | F1000Research, Vol. 10Inhibitory effects of antidepressant fluoxetine on cloned Kv2.1 potassium channel expressed in HEK293 cellsEuropean Journal of Pharmacology, Vol. 878Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis8 January 2020 | Frontiers in Pharmacology, Vol. 10Therapeutic Drug Monitoring in Neuropsychiatric Disorders31 July 2020Therapeutic Drug Monitoring in Neuropsychiatric Disorders23 October 2019Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary Study10 September 2019 | Journal of the American Geriatrics Society, Vol. 67, No. 11Antidepressants are modifiers of lipid bilayer properties22 February 2019 | Journal of General Physiology, Vol. 151, No. 3Toward 19F magnetic resonance thermometry: spin–lattice and spin–spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T4 December 2018 | Magnetic Resonance Materials in Physics, Biology and Medicine, Vol. 32, No. 1Lithium and fluoxetine regulate the rate of phosphoinositide synthesis in neurons: a new view of their mechanisms of action in bipolar disorder31 August 2018 | Translational Psychiatry, Vol. 8, No. 1Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via AstrocytesEBioMedicine, Vol. 32Biological Psychiatry, Vol. 84, No. 1Toxicological Sciences, Vol. 165, No. 2Neuroglia, Vol. 1, No. 2Differential effects of perinatal exposure to antidepressants on learning and memory, acoustic startle, anxiety, and open‐field activity in Sprague‐Dawley rats24 June 2017 | International Journal of Developmental Neuroscience, Vol. 61, No. 1New insights into the intracellular distribution pattern of cationic amphiphilic drugs10 March 2017 | Scientific Reports, Vol. 7, No. 1Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 390, No. 12Toxicology in Vitro, Vol. 45Toxicological Sciences, Vol. 158, No. 2Neuropsychopharmacology, Vol. 41, No. 7PLOS ONE, Vol. 11, No. 10Journal of Alzheimer's Disease, Vol. 51, No. 3The Korean Journal of Physiology & Pharmacology, Vol. 20, No. 4Requirement of AMPK activation for neuronal metabolic-enhancing effects of antidepressant paroxetineNeuroReport, Vol. 26, No. 7Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis31 December 2014 | Oncotarget, Vol. 6, No. 7Journal of Neural Transmission, Vol. 122, No. 9International Journal of Neuropsychopharmacology, Vol. 18, No. 5Molecular Neurobiology, Vol. 49, No. 2Medical Hypotheses, Vol. 82, No. 1The International Journal of Neuropsychopharmacology, Vol. 17, No. 05Trials, Vol. 15, No. 1Selective Serotonin Reuptake Inhibitors (SSRIs) Inhibit Insulin Secretion and Action in Pancreatic β Cells*Journal of Biological Chemistry, Vol. 288, No. 8, Vol. 215Brain Research, Vol. 1490Brain Research, Vol. 1500Molecular and Cellular Neuroscience, Vol. 56Neuroscience, Vol. 247Effect of Amitriptyline on Tetrodotoxin-Resistant Na v 1.9 Currents in Nociceptive Trigeminal Neurons1 January 2013 | Molecular Pain, Vol. 9Dual effects of fluoxetine on mouse early embryonic developmentToxicology and Applied Pharmacology, Vol. 265, No. 1In vitro inhibition of mitochondrial respiratory rate by antidepressantsToxicology Letters, Vol. 213, No. 3The antidepressant drug fluoxetine inhibits persistent sodium currents and seizure-like eventsEpilepsy Research, Vol. 101, No. 1-2Brain Research, Vol. 1466Neuroscience Letters, Vol. 506, No. 2Neuropharmacology, Vol. 62, No. 7Noradrenaline increases neural precursor cells derived from adult rat dentate gyrus through beta2 receptorProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 36, No. 1Epilepsia, Vol. 53, No. 4Epilepsia, Vol. 53, No. 11PLoS ONE, Vol. 7, No. 11NMR in Biomedicine, Vol. 24, No. 2Psychopharmacology, Vol. 214, No. 3European Journal of Neuroscience, Vol. 34, No. 2Basic & Clinical Pharmacology & Toxicology, Vol. 108, No. 1PLoS ONE, Vol. 6, No. 12Interaction of Selective Serotonin Reuptake Inhibitors with Neuronal Nicotinic Acetylcholine Receptors18 June 2010 | Biochemistry, Vol. 49, No. 27Brain Research, Vol. 1336Neuropsychopharmacology, Vol. 35, No. 7European Journal of Neuroscience, Vol. 31, No. 6European Archives of Psychiatry and Clinical Neuroscience, Vol. 259, No. S2Neuropsychopharmacology, Vol. 34, No. 1Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells5 July 2008 | BMC Neuroscience, Vol. 9, No. 1Drug Development Research, Vol. 69, No. 5Brain Research, Vol. 1239Medical Hypotheses, Vol. 70, No. 3Medical Hypotheses, Vol. 70, No. 5Neuroscience Letters, Vol. 442, No. 1Journal of Neurochemistry, Vol. 72, No. 3CNS Neuroscience & Therapeutics, Vol. 14, No. 2Journal of Pharmacological Sciences, Vol. 106, No. 1Inhibition of astroglial Kir4.1 channels by selective serotonin reuptake inhibitorsBrain Research, Vol. 1178FluoxetineMolecular and Cellular Neuroscience, Vol. 36, No. 3Pharmacokinetic Characterization of Amantadine in Human Brain TissueTherapeutic Drug Monitoring, Vol. 28, No. 5NMR in Biomedicine, Vol. 19, No. 6European Archives of Psychiatry and Clinical Neuroscience, Vol. 256, No. 5Neuropharmacology, Vol. 50, No. 4Pharmacology & Therapeutics, Vol. 110, No. 2Nature Neuroscience, Vol. 9, No. 9Molecular Pharmacology, Vol. 69, No. 6BIOMARKERS IN PSYCHOTROPIC DRUG DEVELOPMENT: Integration of Data across Multiple DomainsAnnual Review of Pharmacology and Toxicology, Vol. 45, No. 1Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetineBritish Journal of Pharmacology, Vol. 144, No. 6Monoaminergic‐based Pharmacotherapy for Depression29 January 2008Neuropharmacology, Vol. 48, No. 2Combined actions of zinc and fluoxetine on nicotinic acetylcholine receptors7 September 2004 | The Pharmacogenomics Journal, Vol. 4, No. 6, Vol. 157Brain Research, Vol. 1018, No. 2Clinical Neurophysiology, Vol. 115, No. 9Inhibition of G protein-activated inwardly rectifying K + channels by fluoxetine (Prozac)British Journal of Pharmacology, Vol. 138, No. 6Brain Research, Vol. 973, No. 2Neuroscience Letters, Vol. 346, No. 1-2Biochemical Pharmacology, Vol. 66, No. 11Journal of Pharmacology and Experimental Therapeutics, Vol. 304, No. 3Blood, Vol. 101, No. 8Biological Psychiatry, Vol. 51, No. 3Effect of antidepressants on ATP-dependent calcium uptake by neuronal endoplasmic reticulumCanadian Journal of Physiology and Pharmacology, Vol. 79, No. 11Serotonin reuptake inhibitors fluoxetine and citalopram relax intestinal smooth muscleCanadian Journal of Physiology and Pharmacology, Vol. 79, No. 7Biological Psychiatry, Vol. 49, No. 9Neuropharmacology, Vol. 40, No. 6Neuropharmacology, Vol. 41, No. 4Neuropharmacology, Vol. 39, No. 6Pharmacology & Therapeutics, Vol. 85, No. 1European Neuropsychopharmacology, Vol. 10, No. 5Journal of Cardiovascular Pharmacology, Vol. 35, No. 6Inhibition of neuronal K V potassium currents by the antidepressant drug, fluoxetine30 January 2009 | British Journal of Pharmacology, Vol. 128, No. 7Fluoxetine Dilates Isolated Small Cerebral Arteries of Rats and Attenuates Constrictions to Serotonin, Norepinephrine, and a Voltage-Dependent Ca 2+ Channel OpenerStroke, Vol. 30, No. 9Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca 2+ sensitivityBritish Journal of Pharmacology, Vol. 127, No. 3Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cellsEuropean Journal of Pharmacology, Vol. 367, No. 1Synapse, Vol. 31, No. 4Biological Psychiatry, Vol. 45, No. 10Life Sciences, Vol. 64, No. 9Block by fluoxetine of volume-regulated anion channelsBritish Journal of Pharmacology, Vol. 126, No. 2Magnetic Resonance Spectroscopy in Affective DisordersTadafumi Kato, M.D., Toshiro Inubushi, Ph.D., and Nobumasa Kato, M.D., Ph.D.1 May 1998 | The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 10, No. 2Nuclear Medicine and Biology, Vol. 25, No. 7European Journal of Pharmacology, Vol. 337, No. 1Psychopharmacology, Vol. 126, No. 3Journal of Neural Transmission, Vol. 99, No. 1-3Biological Psychiatry, Vol. 38, No. 10Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 19, No. 4Magnetic Resonance in Medicine, Vol. 31, No. 2Analytical Chemistry, Vol. 66, No. 20Analytical Chemistry, Vol. 66, No. 20 Volume 5Issue 3 August 1993Pages 322-329 Metrics PDF download History Published online 1 April 2006 Published in print 1 August 1993